Compare · LGND vs VKTX
LGND vs VKTX
Side-by-side comparison of Ligand Pharmaceuticals Incorporated (LGND) and Viking Therapeutics Inc. (VKTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LGND and VKTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LGND is the larger of the two at $6.03B, about 1.4x VKTX ($4.41B).
- Over the past year, LGND is up 141.8% and VKTX is up 23.7% - LGND leads by 118.1 points.
- LGND has been more active in the news (11 items in the past 4 weeks vs 1 for VKTX).
- VKTX has more recent analyst coverage (23 ratings vs 9 for LGND).
- Company
- Ligand Pharmaceuticals Incorporated
- Viking Therapeutics Inc.
- Price
- $300.93-3.01%
- $37.97-0.46%
- Market cap
- $6.03B
- $4.41B
- 1M return
- +17.87%
- +32.74%
- 1Y return
- +141.78%
- +23.70%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 11
- 1
- Recent ratings
- 9
- 23
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Viking Therapeutics Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRÃ), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRÃ for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Latest LGND
- Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits
- XOMA Royalty Announces Closing of Its Acquisition by Ligand
- Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
- CLO & Secretary Reardon Andrew acquired $21,214 worth of shares (132 units at $160.71) as part of a pre-agreed trading plan, exercised 5,000 shares at a strike of $52.27 and sold $1,566,377 worth of shares (5,000 units at $313.28) as part of a pre-agreed trading plan, increasing direct ownership by 0.32% to 41,514 units (SEC Form 4)
- Chief Financial Officer Espinoza Octavio acquired $2,732 worth of shares (17 units at $160.71), increasing direct ownership by 0.06% to 27,696 units (SEC Form 4)
- Chief Executive Officer Davis Todd C acquired $21,214 worth of shares (132 units at $160.71), increasing direct ownership by 0.07% to 199,513 units (SEC Form 4)
- Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Ligand Announces Closing of Convertible Senior Notes Offering
- Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering
- SEC Form 8-K filed by Ligand Pharmaceuticals Incorporated
Latest VKTX
- Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
- Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
- SEC Form 4 filed by Chief Medical Officer Chen Hubert C
- SEC Form 3 filed by new insider Chen Hubert C
- Lake Street initiated coverage on Viking Therapeutics with a new price target
- Truist resumed coverage on Viking Therapeutics with a new price target
- Viking Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Viking Therapeutics to Participate at Upcoming Investor Conferences
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
- Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026